- Protecting Consumer Welfare in the U.S. Health Care Sector ( )
- Prepared Statement of the Federal Trade Commission On Pay-For-Delay Deals: Limiting Competition and Costing Consumers ( )
- Statement of Chairwoman Edith Ramirez on “Pay-for- Delay” Settlements ( )
- Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill ( )
- Dissenting Statement of Commissioner Maureen K. Ohlhausen ( )
- Retrospectives at the FTC: Promoting an Antitrust Agenda ( )
- Prepared Statement of the Federal Trade Commission, "Oversight of the Enforcement of the Antitrust Laws" ( )
- Hospital Consolidation: The Good, The Bad, and The Ugly ( )
- Looking Back to Move Forward: Preserving the Progressive Tradition at the FTC ( )
- Comentarios de la Comisionada Edith Ramirez, Foro Latinoamericano de Competencia ( )
- Remarks of Commissioner Edith Ramirez at Latin American Competition Forum 10th Annual Meeting ( )
- Statement of the Federal Trade Commission Concerning the Proposed Acquisition of Medco Health Solutions by Express Scripts, Inc. ( )
- Merial LLC (Frontline Plus) ( )
- Federal Trade Commission and Department of Justice/Antitrust Division Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program ( )
- Prepared Statement of the Federal Trade Commission on Antitrust Enforcement in the Health Care Industry ( )
- Prepared Statement of the Federal Trade Commission: Oversight of the Federal Trade Commission Bureau of Competition and the Department of Justice Antitrust Division ( )
- A Doctor And A Lawyer Walk Into A Bar: Moving Beyond Stereotypes ( )
- FTC's Closure of Its Investigation of Consummated Hospital Merger in Temple, Texas ( )
- Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on the How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context ( )
- A Healthcare Triptych ( )
- Pay-for-Delay Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumer' Wallets, and Help Pay for Health Care Reform (The $35 Billion Solution) ( )
- Emerging Health Care Issues: Follow-on Biologic Drug Competition ( )
- Concurring Statement of Commissioner Jon Leibowitz In re Federal Trade Commission v. Watson Pharmaceuticals et. Al. ( )
- Concurring Statement of Commissioner Jon Leibowitz In re Federal Trade Commission v. Ovation Pharmaceuticals, Inc. ( )
- Tales from the Crypt. Episodes '08 and '09: The Return of Section 5 ("Unfair Methods of Competition in Commerce are Hereby Declared Unlawful") ( )
- Statement of Commissioner Jon Leibowitz Concurring in Part and Dissenting in Part in the Matter of Cephalon, Inc. ( )
- Prepared Statement of the Federal Trade Commission Concerning "The Community Pharmacy Fairness Act of 2007" ( )
- Prepared Statement of the Federal Trade Commission On Protecting Consumer Access To Generic Drugs: The Benefits Of A Leglislative Solution To Anticompetitive Patent Settlements In The Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Internet, and Intellectual Property ( )
- Oral Statement of Commissioner Jon Leibowitz on Anticompetitive Patent Settlements in the Pharmaceutical Industry ( )
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.